Key result
Neoadjuvant chemotherapy linked to a ~200% increase in VTE incidence compared to baseline diagnosis.
Why the study?
What is the incidence of venous thromboembolism in patients with locoregional pancreatic cancer undergoing neoadjuvant chemotherapy, and does it affect surgical resection or overall survival?
What is the incidence of venous thromboembolism in patients with locoregional pancreatic cancer undergoing neoadjuvant chemotherapy, and does it affect surgical resection or overall survival?
In patients with locoregional pancreatic cancer undergoing neoadjuvant therapy, VTE occurs in about 10% of patients but is not associated with decreased rates of surgical resection or overall survival.
Supports vigilant VTE monitoring during neoadjuvant therapy without altering resection candidacy; leaves open the role of prophylaxis in pancreatic cancer.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wright et al. (2026) studied Pancreatic Ductal Adenocarcinoma. Neoadjuvant Chemotherapy was evaluated on Incidence of venous thromboembolism (VTE) during neoadjuvant therapy. During neoadjuvant therapy, 9.9% of patients developed VTE, while 3.3% had VTE at diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: